Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan

References

• Ministry of Health, Labour and Welfare. Basic plan to promote cancer control programs. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000183313.html.
   Google Scholar
• Johnston KM, Sheffield BS, Yip S, et al. Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC). J Med Econ. 2020;23(10):1123–1129.
   PubMed Web of Science ®Google Scholar
• Yu TM, Morrison C, Gold EJ, et al. Budget impact of next-generation sequencing for molecular assessment of advanced non-small cell lung cancer. Value Health. 2018;21(11):1278–1285.
   PubMed Web of Science ®Google Scholar
• Dong L, Wang W, Li A, et al. Clinical next generation sequencing for precision medicine in cancer. Curr Genomics. 2015;16(4):253–263.
   PubMed Web of Science ®Google Scholar
• Sunami K. The challenges of drug provision in cancer genome medicine. Journal of Hereditary Tumors. 2022;21(4):101–104.
   Google Scholar
• Japanese Society of Medical Oncology, Japan Society of Clinical Oncology, Japanese Cancer Association. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment; Edition 2.1; [cited 2020 May 15]. Available from: https://www.jca.gr.jp/researcher/topics/2020/files/20200518.pdf.
   Google Scholar
• Signorovitch J, Zhou Z, Ryan J, et al. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. J Med Econ. 2019;22(2):140–150.
   PubMed Web of Science ®Google Scholar
• Johnston KM, Sheffield BS, Yip S, et al. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact. Curr Oncol. 2020;27(6):e569–e577.
   PubMed Web of Science ®Google Scholar
• Nagino M, Hirano S, Yoshitomi H, et al. Clinical practice guidelines for the management of biliary tract cancers 2019: the 3rd English edition. J Hepatobiliary Pancreat Sci. 2021; Jan28(1):26–54.
   PubMed Web of Science ®Google Scholar
• Okusaka T, Nakachi K, Fukutomi A, et al. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103(4):469–474.
   PubMed Web of Science ®Google Scholar
• Morizane C, Okusaka T, Mizusawa J, et al. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann Oncol. 2019;30(12):1950–1958.
   PubMed Web of Science ®Google Scholar
• Akamatsu H, Ninomiya K, Kenmotsu H, et al. The Japanese lung cancer society guideline for non-small cell lung cancer, stage IV. Int J Clin Oncol. 2019; Jul24(7):731–770.
   PubMed Web of Science ®Google Scholar
• Hashiguchi Y, Muro K, Saito Y, et al. Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020; Jan25(1):1–42.
   PubMed Web of Science ®Google Scholar
• Tourneau CL, Delord JP, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; Oct16(13):1324–1334.
   PubMed Web of Science ®Google Scholar
• Cancer Registry and Statistics. Cancer Prediction. 2015–2039. Cancer information service, National Cancer Center, Japan. https://ganjoho.jp/reg_stat/statistics/dl/index.html.
   Google Scholar
• Center for Cancer Genomics and Advanced Therapeutics. Status of cancer multi-gene panel Tests as of June 2021. https://for-patients.c-cat.ncc.go.jp/registration_status/.
   Google Scholar
• Nikkei Medical Oncology survey. Tests of EGFR, ALK, ROS1, and BRAF gene mutations in 60% before primary treatment for lung cancer. December 3, 2020. https://medical.nikkeibp.co.jp/leaf/mem/pub/search/cancer/report/202012/568090.html.
   Google Scholar
• Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. Nat Med. 2018;24(9):1441–1448.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Akagi K, Oki E, Taniguchi H, et al. Nationwide large-scale investigation of microsatellite instability status in more than 18,000 patients with various advanced solid cancers. J Clin Oncol. 2020;38(4_suppl):803–803.
   Web of Science ®Google Scholar
• Saito M, Shiraishi K, Kunitoh H, et al. Gene aberrations for precision medicine against lung adenocarcinoma. Cancer Sci. 2016;107(6):713–720.
   PubMed Web of Science ®Google Scholar
• Shimizu J, Masago K, Saito H, et al. Biomarker tests for personalized, first-line therapy in advanced nonsquamous non-small cell lung cancer patients in the real world setting in Japan: a retrospective, multicenter, observational study (the BRAVE study). Ther Adv Med Oncol. 2020;12:1758835920904522.
   Web of Science ®Google Scholar
• Matsushita K. BRAF genetic tests in colorectal cancer treatment from the viewpoint of clinical laboratory. Modern Media. 2019;65(5):9–15.
   Google Scholar
• Guidelines for tumor-agnostic genome medicine: Japan society of clinical oncology/Japanese society of medical oncology. Guidelines for tumor-agnostic genome medicine in adult/childhood advanced solid cancer. 2nd version. Kanehara-Shuppan. 2019.
   Google Scholar
• Ishiguro M, Watanabe T, Yoshino T, et al. Examination of the KRAS gene mutation rate in colorectal cancer patients in Japan. 65^th annual meeting of The Japan Society of Coloproctology; 2010.
   Google Scholar
• Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019;30(7):1121–1126.
   PubMed Web of Science ®Google Scholar
• Yoshioka H, Hida T, Nokihara H, et al. Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK + NSCLC). J Clin Oncol. 2021;39(15_suppl):9022–9022.
   Web of Science ®Google Scholar
• André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207–2218.
   PubMed Web of Science ®Google Scholar
• André T, Shiu KK, Kim TW, et al. Final overall survival for the phase III KN177 study: pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). J Clin Oncol. 2021;39(15_suppl):3500–3500.
   Web of Science ®Google Scholar
• Proudman D, DeVito NC, Belinson S, et al. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use. J Med Econ. 2022;25(1):817–825.
   PubMed Web of Science ®Google Scholar